

Alessandra Carobbio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2233902/publications.pdf>

Version: 2024-02-01

111
papers

7,297
citations

57631

44
h-index

54797

84
g-index

113
all docs

113
docs citations

113
times ranked

5455
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. <i>Blood Advances</i> , 2022, 6, 373-375.	2.5	34
2	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	3.3	7
3	Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12657.	1.0	21
4	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. <i>Blood Cancer Journal</i> , 2022, 12, 28.	2.8	31
5	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	3.3	70
6	Response to: Ruxolitinib withdrawal due to the COVID-19. <i>Leukemia</i> , 2021, 35, 1219-1219.	3.3	1
7	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	2.8	26
8	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT JOverlock 10 Tf 50 4	2.2	79
9	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021, 35, 2989-2993.	3.3	34
10	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	2.8	9
11	Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. <i>American Journal of Hematology</i> , 2021, 96, 1580-1586.	2.0	13
12	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. <i>Blood</i> , 2021, 138, 1499-1499.	0.6	1
13	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. <i>Blood</i> , 2021, 138, 236-236.	0.6	2
14	Second <i>Versus</i> First Wave of COVID-19 in Patients with MPN. <i>Blood</i> , 2021, 138, 315-315.	0.6	0
15	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
16	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	2.0	34
17	Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearence, albumin, previous hospital admissions study). <i>European Journal of Internal Medicine</i> , 2020, 72, 60-66.	1.0	5
18	Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 2326-2329.	0.8	1

#	ARTICLE	IF	CITATIONS
19	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 100.	2.8	19
20	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 21.	2.8	35
21	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	0.6	18
22	Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 380-386.	2.5	45
23	Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients. <i>Blood</i> , 2020, 136, 42-43.	0.6	8
24	Symptom Burden in "Low Risk PV" Frequently Is Problematic and May Justify Earlier Intervention with Cytoreductive Therapy: An MPN-QOL Study Group Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	2
25	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	3.3	67
26	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 2391-2399.	1.7	33
27	Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study. <i>World Neurosurgery</i> , 2019, 128, e531-e540.	0.7	11
28	Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. <i>Blood Advances</i> , 2019, 3, 1729-1737.	2.5	105
29	Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?. <i>Blood Advances</i> , 2019, 3, 3951-3952.	2.5	4
30	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	0.6	2
31	Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis. <i>Blood</i> , 2019, 134, 1657-1657.	0.6	0
32	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. <i>American Journal of Hematology</i> , 2018, 93, 698-703.	2.0	31
33	Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. <i>Blood Cancer Journal</i> , 2018, 8, 5.	2.8	20
34	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	2.8	26
35	Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit. <i>Journal of Clinical Pathology</i> , 2018, 71, 330-335.	1.0	15
36	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. <i>Blood Cancer Journal</i> , 2018, 8, 112.	2.8	55

#	ARTICLE	IF	CITATIONS
37	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	0.6	1
38	No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. <i>Haematologica</i> , 2017, 102, e219-e221.	1.7	21
39	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. <i>Journal of Hematology and Oncology</i> , 2017, 10, 54.	6.9	41
40	Diagnostic impact of the 2016 revised who criteria for polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, 417-419.	2.0	26
41	ACE inhibitors and cytoreductive therapy in polycythemia vera. <i>Blood</i> , 2017, 129, 1226-1227.	0.6	14
42	A reappraisal of the benefitâ€risk profile of hydroxyurea in polycythemia vera: A propensityâ€matched study. <i>American Journal of Hematology</i> , 2017, 92, 1131-1136.	2.0	57
43	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. <i>American Journal of Hematology</i> , 2017, 92, E5-E6.	2.0	45
44	Echocardiographic Outflow Pump Ramp Test in Centrifugal-Flow Left Ventricular Assist Device. <i>International Journal of Artificial Organs</i> , 2017, 40, 128-131.	0.7	3
45	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	3.3	75
46	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	2.8	80
47	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1906.	3.8	242
48	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHOâ€criteria and stratified by calendar period of diagnosis. <i>American Journal of Hematology</i> , 2015, 90, 434-437.	2.0	19
49	Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. <i>Blood Cancer Journal</i> , 2015, 5, e369-e369.	2.8	188
50	The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. <i>Annals of Oncology</i> , 2015, 26, 1980-1987.	0.6	88
51	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. <i>Modern Pathology</i> , 2015, 28, 487-497.	2.9	59
52	The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. <i>Leukemia</i> , 2015, 29, 992-993.	3.3	16
53	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1209-1210.	3.3	31
54	Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 4055-4055.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Masked polycythemia vera diagnosed according to WHO and BCSH classification. American Journal of Hematology, 2014, 89, 199-202.	2.0	64
56	Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Network study. American Journal of Hematology, 2014, 89, E200-5.	2.0	42
57	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	1.2	47
58	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 2014, 89, 588-590.	2.0	75
59	Masked polycythemia Vera (mPV): Results of an international study. American Journal of Hematology, 2014, 89, 52-54.	2.0	130
60	Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification. Leukemia, 2014, 28, 2092-2094.	3.3	12
61	PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Annals of Oncology, 2014, 25, 2433-2442.	0.6	119
62	Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infectious Diseases, 2014, 14, 230.	1.3	71
63	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 916-921.	1.7	62
64	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	0.6	112
65	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	0.6	79
66	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	0.6	1
67	Abstract 5604: PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressiveness. , 2014, , .		0
68	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. Blood, 2014, 124, 404-404.	0.6	0
69	Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Experimental Hematology, 2013, 41, 627-634.	0.2	22
70	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia, 2013, 27, 2084-2086.	3.3	51
71	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 2013, 27, 1874-1881.	3.3	540
72	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. Blood, 2013, 122, 4068-4068.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Masked Polycythemia Vera (mPV): Results Of An International Study. <i>Blood</i> , 2013, 122, 1581-1581.	0.6	0
74	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
75	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. <i>Blood</i> , 2012, 119, 2239-2241.	0.6	90
76	A prognostic model to predict survival in 867 World Health Organizationâ€‘defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. <i>Blood</i> , 2012, 120, 1197-1201.	0.6	222
77	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€‘essential thrombocythemia (IPSET-thrombosis). <i>Blood</i> , 2012, 120, 5128-5133.	0.6	461
78	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. <i>Blood</i> , 2012, 120, 569-571.	0.6	69
79	Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. <i>Leukemia</i> , 2012, 26, 716-719.	3.3	149
80	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€‘defined early/prefibrotic myelofibrosis: An international study of 264 patients. <i>American Journal of Hematology</i> , 2012, 87, 669-672.	2.0	49
81	<i>ASXL1</i> mutations in primary and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2012, 156, 404-407.	1.2	17
82	Full-Right-Full-Left Split Liver Transplantation: The Retrospective Analysis of an Early Multicenter Experience Including Graft Sharing. <i>American Journal of Transplantation</i> , 2012, 12, 2198-2210.	2.6	36
83	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 203-204.	2.0	29
84	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. <i>Blood</i> , 2011, 117, 5857-5859.	0.6	376
85	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. <i>Haematologica</i> , 2011, 96, 315-318.	1.7	160
86	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3179-3184.	0.8	441
87	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 814-824.	0.8	151
88	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and) Tj ETQq0 0 0 rgBT /Overlock 10 17 50 137 T		
89	Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients. <i>Blood</i> , 2011, 118, 3846-3846.	0.6	0
90	Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm. <i>Blood</i> , 2011, 118, 5148-5148.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010, 116, 1051-1055.	0.6	56
92	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010, 95, 1435-1438.	1.7	41
93	A pilot study of the Histone Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2010, 150, 446-455.	1.2	202
94	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , 2010, 115, 778-782.	0.6	216
95	Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients. <i>Blood</i> , 2010, 116, 457-457.	0.6	6
96	Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea. <i>Blood</i> , 2010, 116, 1975-1975.	0.6	1
97	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. <i>Experimental Hematology</i> , 2009, 37, 1016-1021.	0.2	89
98	A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. <i>British Journal of Haematology</i> , 2009, 147, 681-685.	1.2	8
99	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. <i>Blood</i> , 2009, 114, 759-763.	0.6	137
100	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , 2009, 114, 2915-2915.	0.6	1
101	High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera.. <i>Blood</i> , 2009, 114, 1911-1911.	0.6	0
102	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. <i>Blood</i> , 2009, 114, 1892-1892.	0.6	0
103	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. <i>Leukemia</i> , 2008, 22, 740-747.	3.3	141
104	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2732-2736.	0.8	169
105	Response: Thrombocytosis in low-risk ET patients. <i>Blood</i> , 2008, 112, 3526-3527.	0.6	2
106	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. <i>Blood</i> , 2008, 112, 3135-3137.	0.6	100
107	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. <i>Blood</i> , 2008, 112, 1745-1745.	0.6	0
108	Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. <i>Blood</i> , 2007, 109, 2310-2313.	0.6	295

#	ARTICLE	IF	CITATIONS
109	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplantation, 2007, 40, 785-791.	1.3	148
110	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia.. Blood, 2007, 110, 681-681.	0.6	0
111	Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiology and Drug Safety, 2005, 14, 31-40.	0.9	34